Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses treatment approaches for elderly/unfit patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, drawing focus on the importance of novel agents and lower-intensity approaches. Dr Kadia first highlights the growing role of venetoclax combined with a hypomethylating agent (HMA), and further discusses the growing role of combination approaches and antibody therapies. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.